<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959474</url>
  </required_header>
  <id_info>
    <org_study_id>20D.876</org_study_id>
    <nct_id>NCT04959474</nct_id>
  </id_info>
  <brief_title>A Research Study to See If Reducing Calories While Undergoing Stereotactic Ablative Radiation Therapy Affects Tumor Growth</brief_title>
  <official_title>SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SABR) With and Without Caloric Restriction for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of calorie reduction while undergoing stereotactic&#xD;
      ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative&#xD;
      radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose&#xD;
      of radiation concentrated on a tumor, while limiting the dose to the surrounding organ.&#xD;
      Giving SABR before surgery may make the tumor smaller. Adding dietary restrictions in&#xD;
      combination with radiation therapy may help increase local control and decrease the spread of&#xD;
      the cancer to other places in the body. The purpose of this trial is to identify if there is&#xD;
      a decrease in tumor tissue in patients undergoing caloric restriction during pre-operative&#xD;
      SABR, compared to patients undergoing pre-operative SABR alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in cellularity of breast tumor</measure>
    <time_frame>Up to 6 weeks after surgery</time_frame>
    <description>The mean percent reduction will be compared between the study arms using a two-sample two-sided t-test with alpha 0.05.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anatomic Stage 0 Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 1 Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 1A Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 1B Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 2 Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 2A Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 2B Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 3 Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 3A Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 3B Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage 3C Breast Cancer AJCC v8</condition>
  <condition>Breast Ductal Carcinoma in Situ</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Prognostic Stage 0 Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 1 Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 1A Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 1B Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 2 Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 2A Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 2B Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 3 Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 3A Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 3B Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage 3C Breast Cancer AJCC v8</condition>
  <condition>Triple Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (standard dietary recommendations, SABR, surgery)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Given standard dietary recommendations</description>
    <arm_group_label>Arm I (standard dietary recommendations, SABR, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>Undergo SABR</description>
    <arm_group_label>Arm I (standard dietary recommendations, SABR, surgery)</arm_group_label>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel Lymph Node Biopsy</intervention_name>
    <description>Undergo sentinel lymph node biopsy</description>
    <arm_group_label>Arm I (standard dietary recommendations, SABR, surgery)</arm_group_label>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (standard dietary recommendations, SABR, surgery)</arm_group_label>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (standard dietary recommendations, SABR, surgery)</arm_group_label>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <description>Undergo a caloric restriction diet</description>
    <arm_group_label>Arm II (caloric restriction diet, SABR, surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with pathologically proven DCIS or invasive breast cancer histologies&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Willing and able to comply with study treatments including dietary intervention&#xD;
&#xD;
          -  Body mass index (BMI) &gt;= 21 at time of enrollment&#xD;
&#xD;
          -  Age &gt;= 40 years at time of consent&#xD;
&#xD;
             * Patients with triple negative breast cancer (TNBC) must be &gt;= 50 years of age at&#xD;
             time of consent&#xD;
&#xD;
          -  Karnofsky performance status (KPS) score 70 - 100&#xD;
&#xD;
          -  Tumor size =&lt; 3.0 cm&#xD;
&#xD;
          -  Gross disease within the breast must be unifocal&#xD;
&#xD;
             * Gross disease may be multifocal as long as the total extent of tumor, gross and&#xD;
             microscopic, occupies a volume with greatest dimension =&lt; 3 cm&#xD;
&#xD;
          -  Patients with invasive disease are required to have axillary staging including&#xD;
             axillary ultrasound (US) that proves patient is clinically node negative&#xD;
&#xD;
          -  Patient is not being considered for preoperative chemotherapy&#xD;
&#xD;
          -  Must be English or Spanish speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is clinically node positive: clinically suspicious axillary lymph node(s) by&#xD;
             axillary US or exam unless biopsied and found to be negative&#xD;
&#xD;
          -  Patient has stage IV metastatic disease&#xD;
&#xD;
             * Patients with oligo-metastatic disease who are being treated with curative intent&#xD;
             per the treating physician will not be excluded if all other eligibility criteria are&#xD;
             met&#xD;
&#xD;
          -  Breast tumor size is &gt; 3.0 cm&#xD;
&#xD;
          -  Positive non-axillary sentinel nodes or evidence of suspicious supraclavicular,&#xD;
             infraclavicular, or internal mammary nodes by imaging or physical exam, unless&#xD;
             biopsied and found to be negative for tumor&#xD;
&#xD;
          -  Evidence by physical examination or mammography of other suspicious masses, densities,&#xD;
             or microcalcifications in either breast, unless biopsied and found to be benign&#xD;
&#xD;
          -  Paget's disease of the nipple&#xD;
&#xD;
          -  Previous breast radiation on ipsilateral side&#xD;
&#xD;
          -  Any prior treatment with radiation therapy or chemotherapy for the current breast&#xD;
             cancer diagnosis prior to registration&#xD;
&#xD;
          -  Patients with significant psychiatric illness that would preclude them from adhering&#xD;
             to the protocol in the judgement of the treating clinician&#xD;
&#xD;
          -  BMI &lt; 21 at the time of study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Simone, MD</last_name>
      <phone>215-955-6702</phone>
      <email>Nicole.Simone@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

